查看購物車
  • English
封面
市場調查報告書
商品編碼
1912616

按製劑形式、技術、治療適應症、最終用戶和通路分類的組合外用藥物市場—2026-2032年全球預測

Compounded Topical Drug Market by Formulation, Technology, Therapeutic Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，複方外用藥物市場價值將達到 51.2 億美元，到 2026 年將成長至 54.1 億美元，到 2032 年將達到 84.2 億美元，年複合成長率為 7.36%。

關鍵市場統計數據
基準年 2025 51.2億美元
預計年份：2026年 54.1億美元
預測年份 2032 84.2億美元
複合年成長率 (%) 7.36%

權威概述了組合外用療法，闡述了臨床需求促進因素、製劑柔軟性以及不斷發展的給藥生態系統。

複方外用製劑處於個人化醫療和實用局部給藥的策略性交會點。在臨床醫師對個人化給藥和製劑柔軟性的需求驅動下，複方外用治療方法需求，彌補了現有標準藥物的不足。在臨床實踐中，這些製劑用於最佳化治療指數、控制輔料不耐受，並在證據和臨床判斷表明有益時支持仿單標示外通訊協定。

監管力度加大、配方創新和數位化醫療服務將如何融合，重塑複方外用藥物的實踐和商業化？

複合外用治療藥物領域正經歷變革性的轉變，這主要由監管、技術和醫療服務三方面因素的融合所驅動。監管機構正在完善指導方針，以加強品管，同時保持個人化配製流程，這促使配製機構投資於標準化流程、完善文件記錄和批次級可追溯性，以滿足日益成長的安全性和透明度要求。

檢驗2025年關稅趨勢對藥局相關人員採購多元化、近岸外包措施和供應鏈韌性策略的影響

美國2025年實施的關稅政策變化，為依賴進口原料、包裝和特殊劑量組件的製造商和配藥機構的供應鏈規劃帶來了更多複雜性。某些輔料和聚合物基質關稅的提高，迫使採購部門重新評估其採購區域，並考慮具有同等品質認證的替代供應商。這些調整通常需要檢驗配方並進行穩定性測試，以確保在引入替代材料時保持治療等效性。

詳細的細分分析揭示了製劑類型、治療用途、通路、最終用戶和貼劑技術如何決定臨床應用和營運優先順序。

細分市場洞察揭示了不同製劑類型、治療適應症、分銷管道、終端用戶環境和底層技術所決定的獨特策略要務。按製劑類型分類的市場分析涵蓋乳膏、泡沫劑、凝膠劑、洗劑、軟膏劑和噴霧劑。每種製劑的應用特性和穩定性各不相同，這會影響處方行為和患者依從性。當潤膚效果是首要考慮因素時，乳膏和洗劑是首選；而凝膠劑和泡沫劑則適用於需要美觀且快速乾燥的應用。當需要封閉或特定接觸模式時，噴霧劑和軟膏劑則發揮獨特的作用。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和監管差異將影響市場准入途徑和商業化策略。

區域趨勢正在影響全球主要市場中複方外用藥物的取得、監管預期和商業化路徑。美洲地區擁有成熟的臨床應用環境，其特點是醫院藥房基礎設施完善，且高度主導。監管機構強調複方製劑的品質標準和不利事件報告，而私人醫療系統通常會整合專科藥房服務，以支持複雜的個人化治療方案。

在局部用藥配送領域，以品質為導向的藥局供應商與以交易為導向的供應商之間的關鍵競爭優勢和夥伴關係模式是什麼？

在複方外用藥物領域，競爭優勢主要體現在三大核心支柱：可驗證的品質系統、以臨床為導向的服務模式以及可擴展的生產和供給能力。領先的複方製劑企業將投資於檢驗的設施、完善的無菌和穩定性測試通訊協定、機構合約以及透明的文件記錄，從而增強臨床醫生的信心。這些投資不僅能降低風險，還能在競標評估和處方集選擇過程中脫穎而出。

為產業領導者提供可操作的策略重點，以協調供應鏈韌性、臨床證據產生和全通路分銷，從而保持競爭優勢。

為確保永續優勢，產業領導者應優先考慮一項三管齊下的行動計劃，該計劃需兼顧供應鏈韌性、臨床證據產生和管道整合。首先，應透過原料來源多元化、盡可能投資近岸外包以及實施包含變更管理和穩定性橋接研究等文件的先進供應商選擇框架來強化供應鏈結構。這些措施將降低關稅和物流波動帶來的風險，並保障患者持續獲得所需藥物。

我們嚴謹且以實踐者觀點的調查方法，整合了深度訪談、監管審查和技術文獻，旨在提供可操作的洞見。

本分析的調查方法結合了結構化的原始研究、監管審查和二手文獻綜述，以確保其全面性和實踐觀點。一級資訊來源包括對醫院藥屋主任、配藥藥劑師、藥房委員會成員和臨床專家的深入訪談，以了解實踐操作和臨床決策促進因素。這些訪談最終得出關於配藥流程、品質預期和實施障礙的定性評估結果。

整合策略要務和實用建議，以協調局部用藥配發中的臨床個體化、營運彈性和監管要求

複方外用製劑是一種可行的個人化局部治療手段，是對傳統藥物傳遞方式的補充。隨著相關人員採納高品質標準、投資製劑創新並重組供應鏈以應對地緣政治因素和關稅帶來的衝擊，該領域正日趨成熟。臨床醫生仍然重視複方製劑的柔軟性，以滿足患者特定的劑量和製劑需求，而採購和監管相關人員相關者正在製定必要的規範，以確保安全可靠的用藥途徑。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：以劑型分類的複方外用藥物市場

  • 奶油
  • 形式
  • 凝膠
  • 洗劑
  • 軟膏
  • 噴

9. 按技術分類的局部用藥市場

  • 傳統配方
  • 經皮貼劑
    • 矩陣補丁
    • 水庫補丁

第10章：依治療適應症分類的複方外用藥物市場

  • 鎮痛/疼痛管理
  • 抗發炎藥
  • 抗菌劑
  • 抗真菌劑
  • 皮膚病
  • 創傷治療

第11章 依最終用戶分類的組合外用藥物市場

  • 診所
    • 一般診所
    • 專科診所
  • 皮膚科診所
  • 居家醫療環境
  • 醫院

第12章 按分銷管道分類的外用藥品市場

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章：各地區組合外用藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 組合外用藥物市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國複方外用藥市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國組合外用藥物市場

第17章：中國複方外用藥市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 3M Company
  • Ascend Laboratories, Inc.
  • Bausch Health Companies Inc.
  • Fagron NV
  • Fresenius Kabi AG
  • Idelle Labs Ltd.
  • ImprimisRx, LLC
  • Merck & Co., Inc.
  • PharMEDium Services, LLC
  • Sun Pharmaceutical Industries Ltd.
Product Code: MRR-AE420CB13A63

The Compounded Topical Drug Market was valued at USD 5.12 billion in 2025 and is projected to grow to USD 5.41 billion in 2026, with a CAGR of 7.36%, reaching USD 8.42 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.12 billion
Estimated Year [2026] USD 5.41 billion
Forecast Year [2032] USD 8.42 billion
CAGR (%) 7.36%

An authoritative overview of compounded topical therapeutics framing clinical demand drivers, formulation flexibility, and the evolving delivery ecosystem

Compounded topical therapeutics occupy a strategic intersection between personalized medicine and practical, localized drug delivery. Driven by clinician demand for tailored dosing and formulation flexibility, compounded topical products enable treatment regimens that address heterogenous patient needs where commercial products may be inadequate. In clinical settings, these preparations are deployed to optimize therapeutic index, manage intolerances to excipients, and support off-label protocols when evidence and clinical judgment indicate benefit.

The broader ecosystem supporting compounded topical drugs includes compounding pharmacies, specialty pharmacists within hospital systems, and an evolving regulatory environment that aims to balance patient safety with access. Technological advancements in formulation science-ranging from novel excipients to controlled-release patch matrices-are enhancing both stability and transdermal penetration profiles. Meanwhile, digital health integration and telemedicine are extending the reach of prescribers and dispensing channels, prompting changes in how clinicians select and monitor topical regimens.

As stakeholders assess product strategy and clinical adoption pathways, understanding the interplay of formulation options, therapeutic indications, distribution channels, and end-user environments becomes essential. This introduction sets the stage for a deeper exploration of the structural shifts, tariff impacts, segmentation nuances, regional dynamics, and actionable recommendations that follow in the report.

How regulatory tightening, formulation innovation, and digitalized care delivery are converging to reshape the practice and commercialization of compounded topical therapeutics

The landscape for compounded topical therapeutics is undergoing transformative shifts driven by converging forces in regulation, technology, and care delivery. Regulators are refining guidance to strengthen quality controls while maintaining pathways for individualized preparations, prompting compounding facilities to invest in standardized processes, enhanced documentation, and batch-level traceability to meet heightened expectations for safety and transparency.

Simultaneously, formulation science is moving from conventional suspensions and creams toward platforms that enable controlled release and improved bioavailability. Advances in transdermal technology and excipient science are creating opportunities to substitute systemic therapy with localized delivery, reducing systemic adverse effects and improving patient adherence. Telehealth and digital prescribing are altering traditional distribution patterns: prescribers can initiate customized regimens remotely, and patients increasingly expect integrated follow-up and digital adherence support.

Commercial dynamics are shifting as well, with contract manufacturers and specialty pharmacies forming partnerships to scale validated compounding operations and provide clinical support services. Procurement teams within hospitals are prioritizing supplier qualification frameworks that emphasize sterility assurance, stability data, and supply continuity. These combined trends are catalyzing new business models where clinical outcome evidence, operational excellence, and regulatory compliance define market leadership.

Assessing how 2025 tariff evolutions are driving sourcing diversification, nearshoring initiatives, and supply chain resilience strategies for compounding stakeholders

Tariff policy changes in the United States during 2025 have layered additional complexity onto supply chain planning for manufacturers and compounding facilities that depend on imported raw materials, packaging, and specialized delivery components. Increased duties on certain excipients and polymer substrates have prompted procurement teams to reassess sourcing geographies and to evaluate alternative suppliers with comparable quality certifications. These adjustments often require revalidation of formulations and stability testing to ensure therapeutic equivalence when substitute materials are introduced.

In response to tariff-induced cost pressure, some organizations have accelerated nearshoring strategies and diversified supplier portfolios to reduce exposure to single-country sourcing. This shift has repercussions for contracting timelines and inventory strategies, triggering higher working capital needs during transitional periods. Logistics providers and specialty distributors have expanded value-added services, including bonded warehousing, deferred duty programs, and vendor-managed inventory solutions, to help clients mitigate cost volatility and maintain continuity of supply for patient care.

Clinicians and hospital procurement teams are adapting by strengthening specifications for raw material traceability and insisting on documented change control processes when substitutions occur. These measures preserve clinical confidence in compounded preparations and support continuity of therapy. Looking forward, tariff-driven realignments are likely to create opportunities for suppliers that can demonstrate robust quality systems, flexible manufacturing capacity, and reliable regional distribution networks.

In-depth segmentation intelligence revealing how formulation types, therapeutic uses, channels, end-users, and patch technologies define clinical adoption and operational priorities

Segmentation-level insights reveal distinct strategic imperatives across formulation types, therapeutic indications, distribution channels, end-user settings, and enabling technologies. Based on Formulation, market analysis covers Cream, Foam, Gel, Lotion, Ointment, and Spray, each offering differentiated application characteristics and stability profiles that influence prescribing behavior and patient adherence. Creams and lotions remain preferred where emollience is prioritized, while gels and foams are selected for cosmetically acceptable, fast-drying applications; sprays and ointments fill niche roles when occlusion or specific contact patterns are needed.

Based on Therapeutic Indication, the study considers Analgesic Pain Management, Anti-Inflammatory, Antibacterial, Antifungal, Dermatological Conditions, and Wound Healing, highlighting how clinical rationale informs formulation choice and dispenser instructions. In pain management and anti-inflammatory use cases, transdermal technologies can provide targeted exposure with reduced systemic burden. Antibacterial and antifungal preparations often require excipients that enhance penetration to the infection site while preserving microbial stability. Dermatological conditions and wound healing applications demand formulations that balance moisture control, barrier support, and active agent stability.

Based on Distribution Channel, analysis covers Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy. The Hospital Pharmacy is further evaluated across Private Hospital Pharmacy and Public Hospital Pharmacy. The Online Pharmacy is examined across Aggregator Platform and Direct Website. The Retail Pharmacy is dissected into Chain Pharmacy and Independent Pharmacy. Each channel presents unique regulatory oversight, inventory management practices, and clinician engagement models. Hospital systems prioritize documented quality systems and traceability, online platforms emphasize digital ordering workflows and remote clinical support, and retail outlets leverage proximity and patient counseling as differentiators.

Based on End User, the assessment addresses Clinics, Dermatology Clinics, Homecare Settings, and Hospitals. The Clinics category is further split into General Clinics and Specialty Clinics, reflecting differences in prescriber expertise, patient volume, and therapeutic focus. Dermatology clinics frequently adopt specialized compounding regimens that require close clinical follow-up, while homecare settings demand packaging and instructions aligned with caregiver capabilities. Hospitals incorporate compounded topicals into inpatient formularies with controlled dispensing protocols and stewardship oversight.

Based on Technology, the report compares Conventional Formulations and Transdermal Patches. The Transdermal Patches are further classified as Matrix Patch and Reservoir Patch, each presenting trade-offs in release kinetics, manufacturing complexity, and regulatory scrutiny. Matrix patches typically offer simpler manufacturing and reduced leak risk, whereas reservoir patches can enable more precise rate control but require robust barrier systems and additional release-testing protocols. These technological distinctions influence supply chain requirements, quality control testing, and clinician education needs.

Regional dynamics and regulatory variance across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine access pathways and commercialization approaches

Regional dynamics shape access, regulatory expectations, and commercialization pathways for compounded topical therapeutics across major global markets. The Americas display a mature clinical adoption environment with sophisticated hospital pharmacy infrastructures and a high degree of clinician-driven customization. Regulatory bodies emphasize compounding quality standards and adverse event reporting, and private health systems often integrate specialty pharmacy services to support complex, personalized regimens.

Europe, Middle East & Africa presents a heterogeneous landscape where national regulatory frameworks differ markedly in their approach to compounding oversight and permitted scopes of practice. In some European jurisdictions, centralized pharmacopoeial standards and robust clinical networks support evidence-driven compounding practices, while other jurisdictions place greater emphasis on regional licensing and local quality controls. The Middle East and Africa regions are seeing increasing investment in capacity building and partnerships with established compounding laboratories to expand access to specialized topical preparations.

Asia-Pacific is characterized by rapid clinical innovation adoption, a growing number of specialty pharmacies, and expanding capabilities in both formulation science and localized manufacturing. Supply chain considerations, including import controls and raw material sourcing, vary across countries, influencing strategic decisions around regional production and distribution. In aggregate, these regional nuances affect how manufacturers prioritize registration pathways, clinical engagement strategies, and partnership models to ensure appropriate access and compliance.

Critical competitive attributes and partnership models that separate quality-driven compounding providers from transactional suppliers in topical therapeutic delivery

Competitive positioning in the compounded topical therapeutics space is anchored in three core pillars: demonstrable quality systems, clinically aligned service offerings, and scalable manufacturing or fulfillment capabilities. Leading compounding organizations invest in validated facilities, robust sterility and stability testing protocols, and transparent documentation that facilitates institutional contracting and clinician confidence. These investments mitigate risk and create differentiation in tender evaluations and formulary decisions.

Service differentiation extends beyond manufacturing to include clinical support, patient counseling, and partnership models with prescribers. Firms that offer evidence summaries, dosing guides, and therapeutic monitoring frameworks strengthen prescriber adoption and support adherence. On the operational side, companies that provide flexible fulfillment options-such as unit-dose packaging, home delivery, and integration with electronic prescribing systems-gain traction among retail and online distribution partners.

Strategic alliances are increasingly common, with specialty pharmacies forming preferred supplier relationships with hospital systems and contract manufacturers providing validated compounding lines for branded drug portfolios. Companies that can demonstrate rapid change control execution, reliable supply continuity, and an integrated approach to regulatory compliance are best positioned to win long-term institutional contracts and support diverse end-user needs.

Actionable strategic priorities for industry leaders to align supply resilience, clinical evidence generation, and omnichannel distribution to sustain competitive advantage

Industry leaders should prioritize a three-part action plan that aligns supply resilience, clinical evidence generation, and channel integration to secure sustainable advantage. First, strengthen supply chain architecture by diversifying raw material sources, investing in nearshoring where feasible, and implementing advanced vendor qualification frameworks that include documented change control and stability bridging studies. These steps reduce exposure to tariff and logistics volatility and support continuous patient access.

Second, commit resources to building clinical evidence and education programs that demonstrate the therapeutic rationale and real-world outcomes of compounded topicals. Collaborative studies with clinical centers, pragmatic registries, and prescriber training initiatives will accelerate appropriate adoption and support payer discussions. Translating clinical experience into clear prescribing guidance and monitoring protocols will also reduce variability in outcomes and reinforce clinician confidence.

Third, invest in channel and technology integration to meet clinicians and patients where they transact care. This includes interoperable e-prescribing interfaces, streamlined digital ordering workflows for aggregator platforms and direct websites, and fulfillment options tailored to hospitals, chain pharmacies, and independent retail outlets. By aligning operational excellence with clinical support and regulatory rigor, leaders can convert trust into enduring commercial relationships.

A rigorous, practitioner-focused research approach combining primary interviews, regulatory review, and technical literature to deliver operationally actionable insights

The research methodology underpinning this analysis combined structured primary research, regulatory review, and secondary literature synthesis to ensure a comprehensive, practice-oriented perspective. Primary inputs included in-depth interviews with hospital pharmacy directors, compounding pharmacists, formulary committee members, and clinical specialists to capture operational realities and clinical decision drivers. These conversations informed qualitative assessments of compounding processes, quality expectations, and adoption barriers.

Regulatory frameworks and guidance documents were reviewed to map compliance requirements and emerging oversight trends that affect compounding practice. The methodology also incorporated a detailed review of technical literature on formulation science, transdermal technologies, and excipient behavior to contextualize practical implications for stability, penetration, and patient acceptability. Supply chain analysis involved consultations with procurement leaders and distributors to understand sourcing constraints, logistics considerations, and tariff-related impacts.

Synthesis prioritized triangulation across sources to validate themes and identify actionable implications. Where variability in practice existed, the approach documented representative workflows and decision criteria rather than relying on single-source assertions. The goal of the methodology was to produce an evidence-based, operationally relevant set of insights that support strategy, procurement, and clinical engagement activities.

Synthesis of strategic imperatives and practical takeaways that reconcile clinical personalization, operational resilience, and regulatory expectations for compounded topicals

Compounded topical therapeutics represent a practical avenue for personalized, localized therapy that complements conventional pharmaceutical offerings. The sector is maturing as stakeholders adopt higher quality standards, invest in formulation innovation, and reconfigure supply chains to address geopolitical and tariff-driven disruptions. Clinicians continue to value the flexibility compounding offers for patient-specific dosing and formulation requirements, while procurement and regulatory stakeholders are shaping the practices needed to sustain safe, reliable access.

Strategically, organizations that can demonstrate validated quality systems, clinical support frameworks, and flexible distribution capabilities are best positioned to capture clinician trust and institutional contracts. Operational resilience-particularly in sourcing and logistics-will remain a differentiator as tariff dynamics and material availability continue to evolve. Meanwhile, transdermal technologies and improved excipient strategies present meaningful opportunities to expand clinical use cases and improve patient experience.

By integrating robust manufacturing controls, clinician-facing evidence, and channel-specific fulfillment solutions, stakeholders can align commercial objectives with patient safety and therapeutic effectiveness. The path forward favors collaborators who can bridge clinical rigor with operational execution and who can translate technical capability into tangible improvements in patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Compounded Topical Drug Market, by Formulation

  • 8.1. Cream
  • 8.2. Foam
  • 8.3. Gel
  • 8.4. Lotion
  • 8.5. Ointment
  • 8.6. Spray

9. Compounded Topical Drug Market, by Technology

  • 9.1. Conventional Formulations
  • 9.2. Transdermal Patches
    • 9.2.1. Matrix Patch
    • 9.2.2. Reservoir Patch

10. Compounded Topical Drug Market, by Therapeutic Indication

  • 10.1. Analgesic Pain Management
  • 10.2. Anti-Inflammatory
  • 10.3. Antibacterial
  • 10.4. Antifungal
  • 10.5. Dermatological Conditions
  • 10.6. Wound Healing

11. Compounded Topical Drug Market, by End User

  • 11.1. Clinics
    • 11.1.1. General Clinics
    • 11.1.2. Specialty Clinics
  • 11.2. Dermatology Clinics
  • 11.3. Homecare Settings
  • 11.4. Hospitals

12. Compounded Topical Drug Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Compounded Topical Drug Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Compounded Topical Drug Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Compounded Topical Drug Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Compounded Topical Drug Market

17. China Compounded Topical Drug Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. 3M Company
  • 18.6. Ascend Laboratories, Inc.
  • 18.7. Bausch Health Companies Inc.
  • 18.8. Fagron N.V.
  • 18.9. Fresenius Kabi AG
  • 18.10. Idelle Labs Ltd.
  • 18.11. ImprimisRx, LLC
  • 18.12. Merck & Co., Inc.
  • 18.13. PharMEDium Services, LLC
  • 18.14. Sun Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COMPOUNDED TOPICAL DRUG MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES COMPOUNDED TOPICAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA COMPOUNDED TOPICAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CREAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CREAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CREAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FOAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FOAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FOAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY GEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY GEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY GEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY LOTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY LOTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY LOTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY OINTMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY OINTMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY OINTMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY SPRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY SPRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY SPRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CONVENTIONAL FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CONVENTIONAL FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CONVENTIONAL FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY MATRIX PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY MATRIX PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY MATRIX PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY RESERVOIR PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY RESERVOIR PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY RESERVOIR PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY ANALGESIC PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY ANALGESIC PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY ANALGESIC PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY ANTI-INFLAMMATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY ANTI-INFLAMMATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY ANTI-INFLAMMATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY ANTIBACTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY ANTIBACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY ANTIBACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY ANTIFUNGAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY ANTIFUNGAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY ANTIFUNGAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DERMATOLOGICAL CONDITIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DERMATOLOGICAL CONDITIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DERMATOLOGICAL CONDITIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY WOUND HEALING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY WOUND HEALING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY WOUND HEALING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY GENERAL CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY GENERAL CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DERMATOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DERMATOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DERMATOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS COMPOUNDED TOPICAL DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE COMPOUNDED TOPICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST COMPOUNDED TOPICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC COMPOUNDED TOPICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN COMPOUNDED TOPICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. GCC COMPOUNDED TOPICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GCC COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 160. GCC COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. GCC COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 162. GCC COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 163. GCC COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. GCC COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 165. GCC COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION COMPOUNDED TOPICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS COMPOUNDED TOPICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. G7 COMPOUNDED TOPICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. G7 COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 184. G7 COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. G7 COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 186. G7 COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 187. G7 COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. G7 COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 189. G7 COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. NATO COMPOUNDED TOPICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. NATO COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 192. NATO COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 194. NATO COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. NATO COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. NATO COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 197. NATO COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES COMPOUNDED TOPICAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA COMPOUNDED TOPICAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)